0.08

Mary E. Ingle a, Deborah Watkins a, Zaira Rosario b, Carmen M. Vélez-Vega b, Antonia M. Calafat c, Maria Ospina c, Kelly K. Ferguson d, José F Cordero e, Akram Alshawabkeh f, John D. Meeker a, \*

**Supplemental Information**


Supplemental Table 1. Demographic characteristics for 48 pregnant women in Puerto Rico

providing up to 3 urine measurements during pregnancy (n=141)

|  |  |  |
| --- | --- | --- |
| Characteristics | Median or n | (IQR or %) |
| Demographic characteristics |  |  |
| Age (years) | 27 | (23, 30) |
| Race/ ethnicity  White  Mestiza  Other | 28 17 3 | (58.3) (35.4) (6.3) |
| Body mass index (kg/m2) | 25.8 | (22.4, 29.0) |
| Ever smoker | 6 | (12.5) |
| Education a  ≤ High school diploma or GED  Some college/technical school/ 2 yr. degree  Bachelor degree  Graduate or doctoral degree | 5 21 14 8 | (10.4) (43.8) (29.2) (16.6) |
| Household Income  ≤ 19,999  20,000-39,999  ≥ 40,000 | 16 20 12 | (33.3) (41.7) (25.0) |
| Characteristics by visit |  |  |
| Gestational age at urine collection (weeks)  Visit 1 b  Visit 2 c  Visit 3 d | 17 24 26 | (16, 20) (22, 25) (26, 29) |

a n=9 missing; b n=3 missing; c n=8 missing; d n=9 missing

Supplemental Figure 1: Correlation matrix (Spearman) for 8-isoprostane, 8-hydroxydeoxyguanosine (OHdG), and urinary OPE metabolites among pregnant women in Puerto Rico



Supplemental Table 2. Regression coefficients (95 %CI) for the association of reported urinary 8-Isoprostane, 8-hydroxydeoxyguanosine and urinary PFR samples among 48 pregnant women (n=141 samples) in the PROTECT cohort

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | PFR a | | | | | | | | | | | | | | | |
|  | BCEtP | | | | BCPP | | | BDCPP | | | DNBP b | | | DPHP | | |
| Biomarkers a | β | | (95%CI) | p | β | (95%CI) | p | β | (95%CI) | p | β | (95%CI) | p | β | (95%CI) | p |
|  |  |  | |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 8-isoprostane | 0.06 | (-0.05, 0.18) | | 0.26 | 0.10 | (-0.01, 0.22) | 0.08 | 0.17 | (0.05, 0.28) | 0.004 | -0.16 | (-0.39, 0.06) | 0.16 | 0.08 | (0.005, 0.16) | 0.04 |
| OHdG | 0.07 | (-0.02, 0.15) | | 0.13 | -0.01 | (-0.10, 0.09) | 0.89 | 0.15 | (0.06, 0.24) | 0.002 | -0.22 | (-0.39, -0.04) | 0.02 | 0.12 | (0.06, 0.18) | 0.0001 |

a natural log transformation; b DNBP modeled as detect/non-detect; p: p-Value; OHdG: 8-hydroxydeoxyguanosine; Models adjusted for SG, age, BMI, gestational age, and income

Supplemental Table 3. Regression coefficients (95 %CI) for the association of reported urinary 8-Isoprostane, 8-hydroxydeoxyguanosine and urinary PFR samples among 48 pregnant women in the PROTECT cohort stratified by visit

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 8-Isoprostane | | | | | | | | |
|  |  | Visit 1 |  |  | Visit 2 |  |  | Visit 3 |  |
|  | β | (95%CI) | p | β | (95%CI) | p | β | (95%CI) | p |
| BCEtP | 0.14 | (-0.10, 0.28) | 0.24 | -0.10 | (-0.27, 0.08) | 0.27 | 0.05 | (-0.14, 0.24) | 0.60 |
| BCPP | 0.02 | (-0.18, 0.23) | 0.82 | 0.07 | (-0.12, 0.27) | 0.44 | 0.10 | (-0.11, 0.30) | 0.34 |
| BDCPP | 0.23 | (0.07, 0.39) | 0.01 | 0.01 | (-0.22, 0.24) | 0.92 | 0.11 | (-0.13, 0.36) | 0.35 |
| DPHP | 0.09 | (-0.05, 0.24) | 0.18 | -0.004 | (-0.14, 0.13) | 0.95 | 0.19 | (0.07, 0.32) | 0.003 |
|  | | | | | | | | | |
|  | 8-hydroxydeoxyguanosine | | | | | | | | |
|  | Visit 1 | | | Visit 2 | | | Visit 3 | | |
|  | β | (95%CI) | p | β | (95%CI) | p | β | (95%CI) | p |
| BCEtP | 0.08 | (-0.08, 0.24) | 0.29 | -0.01 | (-0.17, 0.16) | 0.94 | 0.15 | (-0.002, 0.29) | 0.05 |
| BCPP | -0.03 | (-0.16, 0.11) | 0.71 | -0.01 | (-0.27, 0.10) | 0.34 | 0.09 | (-0.08, 0.26) | 0.28 |
| BDCPP | 0.21 | (0.11, 0.31) | <0.0001 | 0.02 | (-0.20, 0.24) | 0.86 | 0.18 | (-0.02, 0.28) | 0.07 |
| DPHP | 0.11 | (0.03, 0.20) | 0.01 | 0.03 | (-0.11, 0.16) | 0.70 | 0.21 | (0.02, 0.30) | <0.0001 |

Visit 1: n=48 observations, Visit 2: n=46 observations, Visit 3: n=47 observations